Regen Biopharma, Inc. last reported quarterly results on Nov 29, 2024, for Q4 FY2024 (the quarter ended Sep 30, 2024): revenue of $59,366 (+217.2% year over year) and diluted EPS of -$0.01. It usually reports 60 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 60 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 29, 2024
60 days after quarter end
|
Q4 FY2024
ended Sep 30, 2024
|
0
+217.2%
|
-0
+16.7%
|
-0.01
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RGBP (OTC), RGBPP (OTC)
- Fiscal year ends
- September 30
- Incorporated in
- NV
- Headquarters
- La Mesa, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1589150
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.